APUS

Business Context and Reporting Period

Company: Apimeds Pharmaceuticals US, Inc. (APUS)
Reporting Period: Quarter ended March 31, 2026 (10-Q)
Business Model: The Company operates two distinct segments: (1) BioBusiness, a development-stage biopharmaceutical entity focused on Apitox (a honeybee venom-based drug for knee osteoarthritis); and (2) Digital Assets, acquired via the December 2025 merger with MindWave Innovations, holding Bitcoin, Tether, and NILA tokens.
Status: Emerging Growth Company and Smaller Reporting Company. The filing raises substantial doubt about the Company's ability to continue as a going concern due to accumulated deficits and reliance on future financing.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss Expansion: Net loss increased by approximately $34.7 million year-over-year. This is primarily driven by a $22.1 million unrealized loss on digital assets and a significant increase in operating expenses.
• Operating Expenses: Total operating expenses surged from $364k to $12.2 million. This includes a one-time non-cash charge of $8.1 million for advisory shares issued to E.F. Hutton and the initiation of R&D expenses ($901k) for the BioBusiness segment.
• Digital Asset Volatility: The Digital Asset segment, acquired in late 2025, now comprises the majority of the Company's assets ($127.8M). However, the fair value of these assets decreased by approximately $22 million during the quarter, directly impacting the bottom line.
• Liquidity Position: While unrestricted cash decreased slightly, the Company holds $8 million in restricted cash from a PIPE financing tranche. Total cash and restricted cash stands at $8.98 million.

Guidance, Risks, and Unusual Items

• Going Concern: Management explicitly states that conditions raise substantial doubt about the Company's ability to continue as a going concern. Future operations depend on regulatory approvals for Apitox and the performance of volatile digital assets.
• Unusual Non-Cash Items:
  • Advisory Shares: An $8.1 million expense was recorded for 4.5 million shares committed to a financial advisor (2.5 million issued as of filing date).
  • Digital Asset Losses: Unrealized losses of $22.1 million on Bitcoin and NILA tokens.
• Debt and Defaults:
  • The Company has a Senior Secured Convertible Note ($10.9M principal) with a derivative liability component.
  • Subsequent Event: A default notice was received regarding the Senior Secured Note due to disputes involving a Korean affiliate. A forbearance agreement was reached on April 30, 2026, extending until June 30, 2026.
  • Subsequent Event: New promissory notes totaling $3 million were issued to Keren Eliyahu Charitable Trust in May 2026 with high interest rates (120%-125% repayment).
• Internal Controls: Management concluded that disclosure controls and internal controls over financial reporting were not effective due to material weaknesses, including a lack of documented procedures, segregation of duties, and review of journal entries.

Investor Verification Checklist

• Restricted Cash Usage: Verify the specific conditions required to release the $8 million in restricted cash from the PIPE financing.
• Digital Asset Valuation: Confirm the fair value methodology for NILA tokens (Level 2 inputs) and the liquidity of these assets given the reported unrealized losses.
• Debt Curing: Monitor the status of the forbearance agreement regarding the Senior Secured Note and the repayment schedule for the new high-interest promissory notes issued in May 2026.
• Internal Control Remediation: Review the Company's plan to address the material weaknesses in financial reporting controls identified in Item 4.
• Advisory Agreement: Confirm the remaining share issuance obligations to E.F. Hutton and the impact on future dilution.